Efficacy and tolerability of nebivolol in stage i-ii hypertension: A pooled analysis of data from three randomized, placebo-controlled monotherapy trials

Clinical Therapeutics

Volumn 33, Issue 9, 2011, Pages 1150-1161

  Weiss, Robert J ^a   Saunders, Elijah ^b   Greathouse, Mark ^c  

^a Androscoggin Cardiology Associates   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c South Hills Cardiology Associates of Pittsburgh   (United States)

Author keywords

blocker; Clinical trial; Hypertension; Nebivolol; Vasodilatory

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; HEART RATE; HUMAN; HYPERTENSION; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; ETHANOLAMINES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80052991604     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.020     Document Type: Article

References (35)

1. Frishman W.H. Beta-Adrenergic blockers: a 50-year historical perspective. Am J Ther 2008, 15:565-576.
2. Mayor S. NICE removes beta blockers as first line treatment for hypertension. BMJ 2006, 333:8.
3. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007, 1. CD002003.
4. Wright J.M., Musini V.M. First-line drugs for hypertension. Cochrane Database Syst Rev 2009, 3. CD001841.
5. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 2005, 366:1545-1553.
6. Warmack T.S., Estes M.A., Heldenbrand S., Franks A.M. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother 2009, 43:2031-2043.
7. Manrique C., Giles T.D., Ferdinand K.C., Sowers J.R. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich) 2009, 11:369-375.
8. Brewster L.M., van Montfrans G.A., Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004, 141:614-627.
9. Wu J., Kraja A.T., Oberman A., et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005, 18:935-942.
10. Münzel T., Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009, 54:1491-1499.
11. Bystolic (nebivolol) [prescribing information] Accessed May 2010. http://www.frx.com/pi/bystolic_pi.pdf.
12. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol 2010, 33:E20-E27.
13. Weiss R.J., Weber M.A., Carr A.A., Sullivan W.A. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 2007, 9:667-676.
14. Saunders E., Smith W.B., DeSalvo K.B., Sullivan W.A. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 2007, 9:866-875.
15. Lacourciere Y., Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994, 8:283-288.
16. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
17. Scheen A.J. Pharma-clinics medication of the month. Nebivolol (Nobiten). Rev Med Liege 2001, 56:788-791.
18. Lindamood C., Ortiz S., Shaw A., et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 2011, 51:575-585.
19. Petrie A., Sabin C. Medical Statistics at a Glance 2005, Blackwell, Malden, Mass. 2nd ed.
20. Tamhane A.C., Hochberg Y., Dunnett C.W. Multiple test procedures for dose finding. Biometrics 1996, 52:21-37.
21. Ko D.T., Hebert P.R., Coffey C.S., et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002, 288:351-357.
22. Ferdinand K.C., Saunders E. Hypertension-related morbidity and mortality in African Americans-why we need to do better. J Clin Hypertens (Greenwich) 2006, 8(Suppl 1):21-30.
23. Bristow M.R., Nelson P., Minobe W., Johnson C. Characterization of beta1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens 2005, 18:51A-52A.
24. Kamp O., Sieswerda G.T., Visser C.A. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003, 92:344-348.
25. Tzemos N., Lim P.O., MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001, 104:511-514.
26. Le Brocq M., Leslie S.J., Milliken P., Megson I.L. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal 2008, 10:1631-1674.
27. Dzau V.J., Antman E.M., Black H.R., et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006, 114:2850-2870.
28. Dawes M., Brett S.E., Chowienczyk P.J., et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999, 48:460-463.
29. Cockcroft J.R., Chowienczyk P.J., Brett S.E., et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995, 274:1067-1071.
30. Ambrosioni E., Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective B-blockers in the treatment of hypertension. High Blood Press Cardiovasc Prev 2005, 12:27-35.
31. Van Nueten L., Dupont A.G., Vertommen C., et al. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997, 11:139-144.
32. Van Nueten L., Taylor F.R., Robertson J.I. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998, 12:135-140.
33. Neutel JM, Smith DH, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens. Jan;24:64-73.
34. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
35. Wiysonge C.S., Volmink J., Opie L.H. Beta-blockers and the treatment of hypertension: it is time to move on. Cardiovasc J Afr 2007, 18:351-352.